anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hemolytic anemia was observed in approximately 10% of ribavirin/INTRON A-treated subjects in clinical trials. The anemia associated with ribavirin occurs within 1 to 2 weeks of initiation of therapy. Because the initial drop in hemoglobin may be significant, obtain hemoglobin or hematocrit levels before the start of treatment and at week 2 and week 4 of therapy, or more frequently if clinically indicated. Patients should then be followed as clinically appropriate [see Dosage and Administration (2.5, 2.6)].

Fatal and nonfatal myocardial infarctions have been reported in patients with anemia caused by ribavirin. Patients should be assessed for underlying cardiac disease before initiation of ribavirin therapy. Patients with pre-existing cardiac disease should have electrocardiograms administered before treatment and should be appropriately monitored during therapy. If there is any deterioration of cardiovascular status, therapy should be suspended or discontinued [see Dosage and Administration (2.5, 2.6)]. Because cardiac disease may be worsened by drug-induced anemia, patients with a history of significant or unstable cardiac disease should not use ribavirin.
The present invention relates to a Chinese medicine for promoting passage of gas of the anus. The Chinese medicine comprises components in weight portions as follows: 15 to 45 portions of ginger magnolias, 10 to 40 portions of aucklandia roots, 10 to 30 portions of stir-frying oranges and 5 to 15 portions of rhubarb. A preparing method is characterized in that the ginger magnolias and rhababerone are extracted and concentrated; elecampane water is distilled and extracted; the stir-frying oranges and aucklandia root residues are merged, extracted in an aqueous mode and concentrated; finally, a conventional medicinal additive agent is added to form medicinal products of different preparations according to clinic needs. The Chinese medicine can prompt a patient who receives an abdominal operation to discharge gas by the anus and treat enteroparalysis, and has the advantages of stable performance of product quality, less medication dose, short course of treatment, obvious effect and no toxic side effect. The Chinese medicine is particularly suitable for the patients who receiving the abdominal operation, and can make the patient eat in advance, strengthen the organic resistivity of the patients after the operation and prevent various complications after the operation. The preparing method is scientific and reasonable; medicinal material of different medicinal properties is processed in different modes, which ensures the extraction of active ingredients in the medicinal material and facilitates operation. Therefore, the Chinese medicine is suitable for industrial production.
The invention discloses medicinal liquor. Preparing raw materials include traditional Chinese medicine raw materials, 4 kg to 6 kg of first-fen-flavor liquor with the alcoholic strength ranging from 54 degrees to 65 degrees, second-fen-flavor liquor with the alcoholic strength ranging from 60 degrees to 65 degrees and syrup with the sugar content ranging from 10% to 20%. The traditional Chinese medicine raw materials include 70 g to 90 g of bamboo leaves, 35 g to 45 g of pericarpium citri reticulatae, 10 g to 14 g of zingiber kawagoii hayata, 18 g to 22 g of cape jasmine, 8 g to 12 g of flos caryophylli, 6 g to 10 g of feverfew, 10 g to 14 g of holy basil, 6 g to 10 g of sandalwood, 8 g to 12 g of costus roots, 4 g to 8 g of fructus amomi, 6 g to 10 g of angelica roots, 2 g to 6 g of angelica sinensis, 6 g to 10 g of liquorice and 2 g to 6 g of medlar. The alcoholic strength of the prepared medicinal liquor ranges from 38 degrees to 42 degrees. The invention further discloses a preparing method of the medicinal liquor. The medicinal liquor prepared with the technology has the effects of activating blood circulation to dissipate stasis, strengthening the kidney and tonifying the spleen.
Participants in this group will receive the Lattice Extreme Ablative Dose (LEAD) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 8 weeks.
Patients will be submitted to a total parathyroidectomy and 45 fragments of parathyroid tissue are grafted in the forearm. This is the current standard treatment at the institution for severe secondary hyperparathyroidism.The type of operation is the intervention itself. No new device or drug is involved.
Surgical site infections increase patient morbidity and healthcare costs. The Centers for Disease Control and Prevention emphasizes improved basic preventive measures to reduce bacterial transmission and infections for patients undergoing surgery.

Patients undergoing planned oncologic gynecological and plastic surgery will be entered as dyads into a worksheet each day that will rank and select the optimal cases. The research assistants consent both patients in the dyad to the study while they are in the Day of Surgery Admissions area. The first patient in the dyad will receive the bundle, which includes patient decolonization methods, environmental cleaning in the OR, a hand hygiene system located on the IV pole for the anesthesia provider, and intravascular catheter and syringe tip disinfection practices. The second patient in the dyad will receive usual care. Both patients will be surveyed by obtaining swab samples at the beginning and end of the surgery using the OR PathTrac kits. The OR PathTrac kits are obtained from and analyzed for S. aureus isolates by RDB Bioinformatics. The OR PathTrac software (RDB Bioinformatics, Omaha, NE 68154) uses algorithms to guide analysis of the S. aureus isolates and to identify transmission events. Transmission stories are processed by the software to generate transmission maps that identify improvement successes and failures. It also identifies actionable steps to improve the bundle. The perioperative infection control team then uses this information to continually optimize the bundle, and the software to measure the effect.
This study aimed to improve the standardization and suitability of device use and reduce complications associated with intravenous fluids by implementing best practice evidence for intravenous fluid device selection in children. In 2021, the Chinese Journal of Evidence-Based Pediatrics released the " Evidence-based guidelines for clinical practice of intravenous infusion therapy in children". The researchers used the evidence in this guideline as a standard to understand the current status of clinical intravenous infusion device selection and the gap between the current situation and the evidence. The evidence tailor, baseline review, develop implementation plan, conduct implementation research. A stepped wedge cluster randomized trial divided into 5 steps, 10 clusters(units), and the step size was one month. Each included ward of a tertiary first-class pediatric hospital was regarded as a group, and each step was included into randomized two groups, and the observation was maintained for one month until all units were included in the intervention in the fifth month, with a total of 6 research periods. Given the practicality of the study design, limited additional inclusion and exclusion criteria will be added.
The invention discloses a ruthenium complex for inhibiting DNA topoisomerase, which has a molecular formula of [RuL2(PZPP)]Cl2, wherein L is 2,2-bipyridine or 1,10-o-phenanthroline, and PZPP is 3-(2-pyrazinyl)-1,2,4-triazolo[4,5-e]pyrene. The invention also provides the preparation method of the ruthenium complex. The invention further provides a compound 3-(2-pyrazinyl)-1,2,4-triazolo[4,5-e]pyrene obtained in the preparation process of the ruthenium complex. The invention also discloses the application of the ruthenium complex for inhibiting DNA topoisomerase in the preparation of anticancer drugs. The ruthenium complex for inhibiting DNA topoisomerase has good water solubility and has double effects on inhibiting type-I DNA topoisomerase and type-II DNA topoisomerase, and both of the IC50 values are less than 1 muM. The ruthenium complex has wide application prospect.
This study employed a randomized intra-individual design with a split-side axillary approach, comparing the efficacy of 0.025% tretinoin cream against a cream-based formulation. Participants were randomly assigned to apply both 0.025% tretinoin cream and the cream-based product on opposing sides of the axillary region. The efficacy of treatment was assessed by Mexameter (melanin index). The investigator's global evaluation (IGE) and parent's global evaluation (PGE) were also used to evaluate the overall success rate. The local safety was conducted for assessment of any cutaneous irritation. At each visit, the investigator graded the degrees of erythema, dryness, peeling, burning, and itching using a scale of 0 to 4. This study was followed for 4 visits, at the baseline, at week 2, 4 and 8.
FIELD: veterinary medicine. SUBSTANCE: method involves applying ceruloplasmin as serum enzyme antioxidant for treating rabbits. 10 mg of ceruloplasmin is solved in 1 ml of sterile physiological salt solution and injected into a joint once a week during 4-6 weeks. The preparation used is obtained from retroplacental human blood. The preparation shows curative effectiveness when treating rabbits possessing the formed adjuvant arthritis. EFFECT: enhanced effectiveness in treating animals; advised for treating the cases of rheumatoid arthritis in human patients. 2 cl
PROBLEM TO BE SOLVED: To provide a method for extracting a tannin component from raw coffee beans and a method for producing an antioxidant and a deodorant from the resultant extract solution. SOLUTION: A tannin component is extract from unpulverized raw coffee beans with water or an aqueous solution of ethanol at <=60wt.% ethanol concentration. Since the unpulverized raw coffee beans are used, the following effects are obtained: (1) the pulverizing step for the raw coffee beans can be omitted to reduce the production cost, (2) the filtration operations of the extraction solution from the raw coffee beans after completing the extraction are more readily carried out than those from powdery coffee beans and (3) the tannin component is prevented from deteriorating by pulverization. The ethanol concentration is regulated to 30-60wt.% to reduce the extracted amount of unnecessary proteins, etc. Thereby, preservation stability and purity of the tannin component are improved.  In the production of the antioxidant or deodorant, the extracting method of this invention can be applied to a stage for obtaining the tannin composition during the production process to produce the antioxidant or deodorant with good operating efficiency according to a simple process.
Norovirus is highly infectious and rapidly transmissible and represents a major pathogen of sporadic cases and outbreaks of acute gastroenteritis worldwide, causing a substantial disease burden. Recent years have witnessed a dramatic increase in norovirus outbreaks in China, significantly higher than in previous years, among which GII norovirus is the predominant prevalent strain. Therefore, rapid norovirus diagnosis is critical for clinical treatment and transmission control. Hence, we developed a molecular assay based on RPA combined with the CRISPER-CAS12a technique targeting the conserved region of the GII norovirus genome, the results of which could be displayed by fluorescence curves and immunochromatographic lateral-flow test strips. The reaction only required approximately 50 min, and the results were visible by the naked eye with a sensitivity reaching 102 copies/μl. Also, our method does not cross-react with other common pathogens that cause intestinal diarrhea. Furthermore, this assay was easy to perform and inexpensive, which could be widely applied for detecting norovirus in settings including medical institutions at all levels, particularly township health centers in low-resource areas.
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare tumours whose incidence has increased during the years. However, referral centers specialized in diagnosis and treatment of these diseases are few. So, patients may be forced to travel long distances in order to reach a disease specialized center (ENETS certification) to plan the correct management and receive the better treatment. On the other hand, patients could research different clinical consulting by several medical specialists without clear indication. Moreover, today also advanced disease allows the patients a good prognosis with long survival. The resulting emotional and psychological burden may contribute to the worse quality of life. Therefore, patients with GEP-NEN have a deal with the financial consequences related to the diagnosis and treatment of their disease including out of pocket costs, loss of income and caregiver burden. Financial toxicity, defined as subjective financial concerns of cancer and objective financial consequences, has been investigated in this study in Italian patients affected by GEP-NEN
Apheresis blood donation maximizes an individual's donation by selecting specific blood components that are used to save patient lives. Dramatic increases in the number of apheresis procedures performed each year are apparent both domestically and internationally. Apheresis requires the use of citrate anticoagulation, a substance that confers its anticoagulant effect through chelation of cations, like calcium. A small number of cross-sectional studies have reported that intermittent exposure to citrate through apheresis is associated with significant declines in donor bone mineral density (BMD). In contrast, oral potassium citrate of much lower dose has been used to treat low bone density with well-documented efficacy. The impact of citrate exposure during apheresis, either positive or negative, is important given that BMD is a significant risk factor for low trauma fracture, a problem that affects more than 2M people in the U.S. annually. It is ultimately unknown what effect repeated apheresis has on skeletal health. To address this knowledge gap, we will perform a Phase IV clinical trial of apheresis blood donors using a cross-disciplinary, multi-institutional team. As apheresis blood donation continues to affect more people, the importance of understanding the effects of repeated exposure to citrate on donor skeletal health is essential in protecting this precious community resource.
BACKGROUND: Ischaemic end-organ damage during haemodialysis (HD) is a significant problem that may be ameliorated by intradialytic cooling. A randomised trial was performed to compare standard HD (SHD; dialysate temperature 37°C) and programmed cooling of the dialysate [thermocontrolled HD (TCHD)] using multiparametric magnetic resonance imaging (MRI) to assess structural, functional and blood flow changes in the heart, brain and kidneys.
METHODS: Prevalent HD patients were randomly allocated to receive either SHD or TCHD for 2 weeks before undergoing serial MRI at four time points: pre-, during (30 min and 180 min) and post-dialysis. MRI measures include cardiac index, myocardial strain, longitudinal relaxation time (T1), myocardial perfusion, internal carotid and basilar artery flow, grey matter perfusion and total kidney volume. Participants then crossed to the other modality to repeat the study protocol.
RESULTS: Eleven participants completed the study. Separation in blood temperature between TCHD (-0.1 ± 0.3°C) and SHD (+0.3 ± 0.2°C; P = .022) was observed, although there was no difference in tympanic temperature changes between arms. There were significant intradialytic reductions in cardiac index, cardiac contractility (left ventricular strain), left carotid and basilar artery blood flow velocities, total kidney volume, longitudinal relaxation time (T1) of the renal cortex and transverse relaxation rate (T2*) of the renal cortex and medulla, but no differences between arms. Pre-dialysis T1 of the myocardium and left ventricular wall mass index were lower after 2 weeks of TCHD compared with SHD [1266 ms (interquartile range 1250-1291) versus 1311 ± 58 ms, P = .02; 66 ± 22 g/m2 versus 72 ± 23 g/m2, P = .004].
CONCLUSIONS: HD adversely affects cardiac function, reduces carotid and basilar artery blood flow and total kidney volume, but mild dialysate cooling using a biofeedback module did not result in differences in intradialytic MRI measures compared with SHD.
In this study, there will be 2 procedure performed. The first procedure will be named P1 and consists of subcutaneous injection of either placebo or Botulinum Toxin A. The second procedure will be the cross-over procedure named P2. For the cross-over procedure, the subjects who had initially received Botulinum Toxin A will receive placebo and the subjects who had initially received placebo will receive Botulinum Toxin A. This is a Randomized Double-Blinded Placebo Controlled Trial. Recruited subjects will be consented, enrolled and evaluated immediately prior to P1 (or during a visit prior to the visit for P1). After the initial pre-treatment evaluation, subjects will randomly receive either placebo or Botulinum Toxin A subcutaneously (P1). A telephone follow-up (or e-mail follow up) will be performed at 2 weeks and 8 weeks post- P1. An onsite follow up will be performed 4 weeks post P1 and 12 weeks post P1.

Cross-over Study: After the 3rd month on-site evaluation (12 weeks post P1), during the same visit, the subject will proceed to the cross-over study. At this time, the patient will have the option to receive a repeat subcutaneous injection of the cross-over agent. If they desire one, a subcutaneous injection of the cross-over agent will be performed at that same visit. If they wish to defer the repeat injection, they will be contacted and asked every 4 weeks - between 12 weeks and 24 weeks post P1 (no subject will receive P2 after week 24) if they would like to have the subcutaneous injection of the cross-over agent. If they desire one, a repeat injection will be scheduled for the following week.

The rationale for a variable length of time after the initial Botulinum Toxin A/Placebo injection (P1) is to document the variability of individuals' pain response after Botulinum Toxin A. It has been reported in literature, of the subjects that respond to subcutaneous Botulinum Toxin A injections for pain, most will return to their base-line pain score in 12--24 weeks.
PURPOSE:To provide a hair-improving agent composed of an antibody having immunoreactivity to proteins existing in the cuticle of human hair and effective for protecting the damage of hair and improving the gloss, softness, feeling, etc., of the hair. CONSTITUTION:An antigen composed mainly of cuticle proteins having molecular weights of 55K-Dalton and 65K-Dalton is obtained by extracting cuticle of human hair with a solution containing a reducing agent (e.g. 2-mercaptoethanol) and a modifying agent (e.g. urea). An antibody is produced by immunizing mammals or birds with the antigen by conventional method and the antibody is used as a component of the objective hair-modifying agent. The hair-modifying agent can be used in the form of shampoo, rinse, etc., by compounding to a composition for hair. The anti-cuticle protein antibody has strong affinity to a completely keratinized hair and specifically binds to the hair to improve the breaking strength of the hair.
The observational findings of Barker's original epidemiological studies were generalized as the Barker hypothesis and extended as the Developmental Origins of Health and Disease (DOHaD) theory. Barker et al. proposed that low birthweight (LBW) was associated with the occurrence of various noncommunicable diseases (NCDs) later in life. In other words, LBW itself is associated with the development of NCDs. This led to the DOHaD theory which proposed that an organism may have a specific period of developmental plasticity that is highly sensitive to the factors in its environment, and that combinations of acquired constitution and environmental factors may adversely affect health and risk the formation of NCDs. Due to undernutrition during the fetal period, the fetus acquires an energy-saving constitution called a thrifty phenotype due to adaptations of the metabolic and endocrine systems. It has been suggested that stimuli experienced early in development can persist throughout life and induce permanent physiological changes that predispose to NCDs. It has since become clear that the adverse environmental effects during the prenatal period are also intergenerationally and transgenerationally inherited, affecting the next generation. It has been shown that nutritional interventions such as methyl-donner and epigenome editing can restore some of the impaired functions and reduce the risk of developing some diseases in the next generation. This review thus outlines the mechanisms underlying various disease risk formations and their genetic programs for the next generation, which are being elucidated through studies based on our fetal undernutrition rat models.
The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws.
The invention discloses an application of Houttuynoid A in preparation of blood sugar reducing medicines. The invention provides a brand-new selection and concept for current anti-diabetic medicines, expands the selective field of anti-diabetic medicines and contributes to development of the technical field. The application of Houttuynoid A provided by the invention is proved to have a remarkable anti-diabetic effect. In the invention, a compound with a explicit chemical structure is selected. The application of Houttuynoid A in preparation of blood sugar reducing medicines is disclosed for the first time. As the framework type belongs to a brand-new framework type and the activity for preventing and treating diabetic is previously unimagined, the probability of giving any inspiration by other compounds is not available, so that the Houttuynoid A has a protruding substantial characteristic and meanwhile is remarkably progressive for treating diabetic.
Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 3 months. Participants will receive a daily dose of placebo for these 3 months, then given the option to receive a daily dose of probiotic ABB C3 for 3 more months.
Novel methods and compositions are provided for modulating homing of leukocytes, particularly lymphocytes, where the compounds are cross-reactive with or contain Neu5Ac2-3Gal.beta.1-x[Fuc.alpha.1-y]GlcNAc, where one of x and y is 3 and the other is 4. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration and for directing molecules to such sites. In addition, methods and compositions are disclosed for the inhibition of cancer metastases mediated by endothelial adhesion molecules. The present invention discloses that sialyl-Lea and di-sialyl-Lea, which are expressed at the surface of cancer cells, function as a binding partner for selectins, such as ELAM-1, which are expressed at the surface of endothelial cells. The present invention also discloses that selectins, such as ELAM-1, LECAM-1 and GMP-140, bind a carbohydrate domain common to both sialyl-Lea and sialyl-Lex.  Antibodies, saccharides, glycoconjugates, enzymes, enzyme inhibitors and other molecules may be used in the methods of the present invention to inhibit the binding of malignant cells to endothelial cells for a variety of purposes in vivo and in vitro.